Razavi HA, Waked I, Qureshi H, Kondili LA, Duberg AS, Aleman S, Tanaka J, Lazarus JV, Low-Beer D, Abbas Z, Rached AA, Aghemo A, Aho I, Akarca US, Al-Busafi SA, Al-Hamoudi WK, Al-Naamani K, Alaama AS, Aldar MM, Alghamdi M, Gonzalez MA, Alserehi H, Anand AC, Asselah T, Assiri AM et al. (2025)
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies
J Hepatol (in press)
DOI 10.1016/j.jhep.2025.01.013, PubMed 39914746

Fretheim H, Barua I, Bakland G, Dhainaut A, Halse AK, Carstens MN, Didriksen H, Midtvedt Ø, Lundin KEA, Aabakken L, Sarna VK, Zaré HK, Khanna D, Distler O, Midtvedt T, Bækkevold ES, Olsen IC, Domanska D, Pesonen ME, Molberg Ø, Hoffmann-Vold AM (2025)
Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial
Lancet Rheumatol (in press)
DOI 10.1016/S2665-9913(24)00334-5, PubMed 39900089

Whittaker R, Midgard H, Dalgard O, Kløvstad H (2024)
Treatment uptake among notified cases of hepatitis C virus infection in Norway, 1990 to 2022: a registry-based study to monitor progress towards elimination
Euro Surveill, 29 (46)
DOI 10.2807/1560-7917.ES.2024.29.46.2400180, PubMed 39544147